difficulty of understanding HVDPs [RSABE / ABEL]

posted by khaoula – Algeria, 2014-09-08 17:01 (3517 d 04:18 ago) – Posting: # 13464
Views: 4,236

Hi Everybody , I have big problem to understand what's HVDP's
soI read : HVDPs are products in which the drug is not highly variable, but the product is of poor pharmaceutical quality and high within-formulation variability, so What’s the difference between : Within formulation variability and Subject by formulation interaction? Is subject by formulation interaction contribute to high CVW ( >30%) in HVDPs?
I confounds between the two , for me subject by formulation interaction is inter-individual variability, when the excipients in a formulation influence physiological variables, or the physicalchemical properties of a formulation and/or its drug, in the gastro intestinal tract
thank you :)

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,652 registered users;
147 visitors (0 registered, 147 guests [including 6 identified bots]).
Forum time: 21:19 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5